Literature DB >> 36032987

Management of Intracranial Sinusitis Complications in Children and Adolescents: Similarities and Differences Among Otolaryngology Subspecialists.

Eelam Adil1,2, Jamie J Kim1, Kosuke Kawai1,2, Michael J Cunningham1,2.   

Abstract

The purpose of this study was to compare the management of intracranial sinusitis complications in pediatric patients between members of the American Rhinologic Society (ARS) and the American Society of Pediatric Otolaryngology (ASPO). A cross-sectional web-based survey was distributed twice to the ASPO and ARS membership over an 8-month period. The overall survey response rate was 12.1% (7.5% of ARS members and 17.3% of ASPO members). Recommended management was similar with respect to the use of intravenous antibiotics, nasal saline irrigations, topical decongestants, and nasal steroid sprays. Recommendations diverged with regards to systemic steroid use and urgent/emergent endoscopic sinus surgery (ESS). ARS members were more likely to recommend systemic corticosteroids. ASPO members were more likely to recommend immediate ESS. Based on survey responses, we found differences in practice patterns among subspecialists, which indicates additional collaborative research between societies is necessary to develop and disseminate evidence-based guidelines for these patients. Level of Evidence: 4.
© The Authors 2022.

Entities:  

Keywords:  ARS; ASPO; complications; intracranial; management; pediatric; sinusitis

Year:  2022        PMID: 36032987      PMCID: PMC9400408          DOI: 10.1177/2473974X221120635

Source DB:  PubMed          Journal:  OTO Open        ISSN: 2473-974X


Intracranial sinusitis complications (ISCs) are infrequent but have significant morbidity. Notably, 63% of epidural and subdural abscesses in the pediatric age group are of sinus origin. Children are thought to be more susceptible to such complications due to thinner osseous sinus walls, larger vascular foramina, and patent suture lines.[2,3] The initiation of intravenous (IV) antibiotic therapy as treatment of suspected ISC is uniformly accepted. There is less consensus with respect to additional medical and surgical management, including recent literature questioning the benefit of endoscopic sinus surgery (ESS) with respect to outcomes including length of stay, need for revision surgery, transfusion, persistent neurologic morbidity, or readmissions.[4,5] The purpose of this study is to evaluate practice patterns among members of the American Rhinological Society (ARS) and the American Society of Pediatric Otolaryngology (ASPO) given the likelihood these 2 subspecialist groups care for children with ISC.

Methods

This survey study was exempt from Boston Children’s Institutional Review Board. An anonymous 8-question survey (see Supplemental Table S1 in the online version of the article) focusing upon management options for ISC was developed. The survey was reviewed and approved by the ARS and ASPO Research Committees and subsequently electronically distributed to both memberships twice over an 8-month period. The survey was accessed via a survey link through Survey Monkey. A binomial regression model with log-link function compared ASPO vs ARS responses. Results were tabulated using RedCap software and R statistical software.

Results

Of the 1504 individuals invited, 182 (12.1%) completed the survey: 66 (7.5%) of 875 ARS members and 110 (17.3%) of 635 ASPO members; 6 respondents reported dual membership. Almost all respondents (>98%) recommended IV antibiotic therapy. Most respondents recommended nasal saline irrigations (71%-78%), nasal decongestants (79%-85%), and nasal steroid sprays (57%-59%). The use of systemic corticosteroids ranged from 30% to 40% depending upon the specific ISC. Half of the respondents (50%) recommended immediate ESS in the meningitis case, with this percentage increasing to 75% for epidural abscess, 76% for subdural abscess, 76% for cerebral abscess, and 86% for cavernous sinus thrombosis. ARS members were approximately twice as likely to recommend systemic corticosteroids for all types of ISC ( ). Recommendations as to the use of intravenous antibiotics, nasal saline irrigations, topical nasal steroid spray, and topical nasal decongestant did not differ significantly. ASPO members were significantly more likely to recommend urgent/emergent ESS than ARS members for the management of epidural abscess (88% vs 59%), subdural abscess (86% vs 56%), cerebral abscess (84% vs 61%), and cavernous sinus thrombosis (93% vs 74%). There was no significant difference between societies regarding recommended neurosurgical intervention.
Table 1.

Management of Intracranial Sinusitis Complications by Society Membership.

ManagementASPO (n = 110), %ARS (n = 66), %RR (95% CI) P value
IV antibiotics
 Meningitis10098.5
 Epidural abscess99.197.01.02 (0.98-1.07).36
 Subdural abscess98.297.01.02 (0.96-1.06).62
 Cerebral abscess99.197.01.02 (0.98-1.07).36
 Cavernous sinus thrombosis99.197.01.02 (0.98-1.07).36
Nasal saline irrigations
 Meningitis80.074.21.08 (0.91-1.28).39
 Epidural abscess72.777.30.94 (0.79-1.12).49
 Subdural abscess72.777.30.94 (0.79-1.12).49
 Cerebral abscess71.872.70.99 (0.82-1.19).90
 Cavernous sinus thrombosis73.672.71.01 (0.84-1.22).90
Topical nasal steroid spray
 Meningitis57.363.60.90 (0.71-1.15).40
 Epidural abscess55.566.70.83 (0.65-1.06).13
 Subdural abscess52.766.70.79 (0.62-1.01).06
 Cerebral abscess53.663.60.84 (0.66-1.08).18
 Cavernous sinus thrombosis53.662.10.86 (0.67-1.12).26
Topical nasal decongestant
 Meningitis89.177.31.15 (0.99-1.33).06
 Epidural abscess80.974.21.09 (0.92-1.29).32
 Subdural abscess85.577.31.11 (0.95-1.29).19
 Cerebral abscess86.475.81.14 (0.98-1.33).10
 Cavernous sinus thrombosis87.374.21.18 (1.00-1.38).05
Systemic corticosteroid
 Meningitis25.545.50.56 (0.37-0.85).006
 Epidural abscess21.845.50.48 (0.31-0.75)<.001
 Subdural abscess25.547.00.54 (0.36-0.82).003
 Cerebral abscess25.554.60.47 (0.32-0.69)<.001
 Cavernous sinus thrombosis32.751.50.64 (0.45-0.91).012
Urgent/emergent endoscopic sinus surgery
 Meningitis52.743.91.20 (0.87-1.66).27
 Epidural abscess88.259.11.49 (1.21-1.84)<.001
 Subdural abscess86.456.11.54 (1.23-1.93)<.001
 Cerebral abscess83.660.61.38 (1.12-1.70).003
 Cavernous sinus thrombosis92.774.21.25 (1.07-1.45).004
Craniotomy
 Meningitis00
 Epidural abscess45.440.91.11 (0.78-1.58).56
 Subdural abscess63.674.20.86 (0.70-1.05).13
 Cerebral abscess73.677.30.95 (0.80-1.13).58
 Cavernous sinus thrombosis10.93.03.60 (0.83-15.59).09

Abbreviations: ARS, American Rhinological Society; ASPO, American Society of Pediatric Otolaryngology; IV, intravenous; RR, risk ratio.

RR (ASPO vs ARS) and 95% CI were estimated from the binomial regression model with a log-link function.

Management of Intracranial Sinusitis Complications by Society Membership. Abbreviations: ARS, American Rhinological Society; ASPO, American Society of Pediatric Otolaryngology; IV, intravenous; RR, risk ratio. RR (ASPO vs ARS) and 95% CI were estimated from the binomial regression model with a log-link function.

Discussion

This survey demonstrates universal congruence regarding the role of intravenous antimicrobial therapy in the management of ISC. ARS and ASPO members are also uniformly supportive of nasal saline irrigations, topical nasal steroid sprays, and topical nasal decongestants and similarly acknowledge the need for neurosurgical intervention. However, 2 important differences in recommended medical and surgical management are evident according to society membership. ARS members are more likely to recommend systemic corticosteroids for ISC than their ASPO counterparts. This result contrasts with a prior study reporting ARS members to be nearly 3 times less likely than ASPO members to prescribe systemic steroids for orbital sinusitis complications. The difference in management for orbital vs intracranial sinusitis complications is unclear but likely reflects the lack of established efficacy for systemic steroid therapy for these indications. With the exception of meningitis, ASPO members were more likely to recommend immediate ESS in the management of all ISC scenarios. Societal differences aside, among the 5 scenarios, the majority of total respondents (ranging from 50% for meningitis to 85.7% for cavernous sinus thrombosis) did recommend ESS. Such is consistent with current literature documenting ESS is performed in most (62.5%-100%) cases.[7-13] Despite its frequent use, the benefit of urgent/emergent ESS remains controversial. A retrospective database assessment documented no significant outcome improvement in patients with ISC who underwent ESS in conjunction with a neurosurgical procedure compared to those who underwent a neurosurgical procedure alone. A more recent pediatric-specific ISC case series similarly concluded the benefit of frontal sinus drainage with respect to measured clinical outcomes was unclear. Although ESS is safe in experienced hands, it is still a surgical intervention that requires general anesthesia, and therefore it is important for future research to continue to question whether or not there is a role for ESS in these cases. This study has several limitations. The response rates, although comparable to those of similar survey-based studies, are unfortunately low.[6,14,15] The survey was purposefully brief in an attempt to engage more physicians and increase the response rate. In doing so, questions regarding the timing/duration of therapeutic interventions, comorbidities, orbital complications, and other complicating considerations were not included and may have affected response selections. Finally, survey respondents were subspecialists who practice primarily in academic settings (75.3% of respondents). Their opinions regarding management may diverge from those practicing comprehensive otolaryngology in the community. Although differences in management based on subspecialty may not be clinically relevant, it is important as academic otolaryngologists to recognize there are differences in practice patterns likely due to training and patient populations. This is particularly important when discussing these cases among trainees as they may receive conflicting opinions between subspecialists.

Conclusion

This survey study exhibits some divergences in subspecialty practice patterns and points to the need for more collaborative research to determine optimal ISC management and enhance patient outcomes.

Author Contributions

Eelam Adil, study conception and design, acquisition of data, analysis and interpretation of data, drafting of manuscript, critical revision of manuscript; Jamie J. Kim, acquisition of data, drafting of manuscript; Kosuke Kawai, analysis and interpretation of data, drafting of manuscript; Michael J. Cunningham, study conception and design, analysis and interpretation of data, critical revision of manuscript

Disclosures

Competing interests: None. Sponsorships: None. Funding source: None. Click here for additional data file. Supplemental material, sj-docx-1-opn-10.1177_2473974X221120635 for Management of Intracranial Sinusitis Complications in Children and Adolescents: Similarities and Differences Among Otolaryngology Subspecialists by Eelam Adil, Jamie J. Kim, Kosuke Kawai and Michael J. Cunningham in OTO Open: The Official Open Access Journal of the American Academy of Otolaryngology-Head and Neck Surgery Foundation
  15 in total

Review 1.  Microbiology and antimicrobial treatment of orbital and intracranial complications of sinusitis in children and their management.

Authors:  Itzhak Brook
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2009-02-26       Impact factor: 1.675

Review 2.  Treatment of pediatric extra-axial sinogenic infection: case series and literature review.

Authors:  Mandana Behbahani; Laura Burokas; Clayton L Rosinski; David M Rosenberg; Nauman S Chaudhry; Jonathan M Sherman; Demitrios C Nikas
Journal:  Childs Nerv Syst       Date:  2019-11-26       Impact factor: 1.475

3.  Intracranial complications of pediatric sinusitis: Identifying risk factors associated with prolonged clinical course.

Authors:  Alexander J Schupper; Wen Jiang; Michael J Coulter; Matthew Brigger; Javan Nation
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2018-06-12       Impact factor: 1.675

4.  Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years.

Authors:  Ellen R Wald; Kimberly E Applegate; Clay Bordley; David H Darrow; Mary P Glode; S Michael Marcy; Carrie E Nelson; Richard M Rosenfeld; Nader Shaikh; Michael J Smith; Paul V Williams; Stuart T Weinberg
Journal:  Pediatrics       Date:  2013-07       Impact factor: 7.124

5.  Practice patterns in pediatric chronic rhinosinusitis: A survey of the American Rhinologic Society.

Authors:  Daniel M Beswick; Hassan Ramadan; Fuad M Baroody; Peter H Hwang
Journal:  Am J Rhinol Allergy       Date:  2016-11-01       Impact factor: 2.467

6.  Outcomes of endoscopic sinus surgery for sinusitis-induced intracranial abscess in patients undergoing neurosurgery.

Authors:  Megumi Koizumi; Miho Ishimaru; Hiroki Matsui; Kiyohide Fushimi; Tatsuya Yamasoba; Hideo Yasunaga
Journal:  Neurosurg Focus       Date:  2019-08-01       Impact factor: 4.047

7.  Intracranial complications of sinusitis: a pediatric series.

Authors:  C Giannoni; M Sulek; E M Friedman
Journal:  Am J Rhinol       Date:  1998 May-Jun

8.  Reducing Surgical Revisions in Intracranial Complications of Pediatric Acute Sinusitis.

Authors:  Sarah A Gitomer; Wei Zhang; Lucila Marquez; Binoy M Chandy
Journal:  Otolaryngol Head Neck Surg       Date:  2018-03-27       Impact factor: 3.497

9.  Practice Patterns of Systemic Corticosteroid Use in Complicated Acute Rhinosinusitis Among Rhinologists and Pediatric Otolaryngologist.

Authors:  Derek Wu; Jason Wasserman; Marina Boruk
Journal:  Am J Rhinol Allergy       Date:  2018-08-30       Impact factor: 2.467

10.  Intracranial complications of pediatric rhinosinusitis: Identifying risk factors and interventions affecting length of hospitalization.

Authors:  Corina Din-Lovinescu; Ghayoour Mir; Conor Blanco; Kevin Zhao; Thomas Mazzoni; Arno Fried; Mostafa El Khashab; Giant Lin
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2019-12-19       Impact factor: 1.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.